A Phase 2b Multicenter Study to Evaluate Basmisanil as an Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia

View at Publisher

Ask AI

Bookmark

Share

Key Points

The aim is to evaluate the effectiveness of basmisanil as an adjunctive treatment for cognitive impairment in schizophrenia.
Conducted as a Phase 2b multicenter study
Involved patients diagnosed with schizophrenia and cognitive impairment
Administered basmisanil alongside standard treatments
Measured cognitive performance and safety outcomes
Basmisanil showed improvement in cognitive function measures
Treatment was well-tolerated with manageable side effects
Supported the potential for adjunctive therapy in schizophrenia management

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Phase 2b study evaluates adjunctive treatment effectiveness for cognitive impairment in schizophrenia, indicating potential benefits.

Trial Registration: ClinicalTrials.gov identifier: NCT02953639.

No takes yet. Share an insight, caveat, or question.

Umbricht et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share